TL-895 and KRT-232 Study in Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This study evaluates TL-895, a potent, orally available and highly selective irreversible
tyrosine kinase inhibitor combined with KRT-232, a novel oral small molecule inhibitor of
MDM2 for the treatment of adults with FLT3 mutated Acute Myeloid Leukemia. Participants must
be relapsed/refractory (e.g., having failed prior therapy) to be eligible for this study.